4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Zenas BioPharma, Inc. (ZBIO) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 167 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ZBIO reported $10M in revenue and ($378M) in net income.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $10M | $5M | $50M | $0M |
| Operating Income (EBIT) | ($211M) | ($164M) | ($27M) | ($75M) |
| Net Income | ($378M) | ($157M) | ($37M) | ($119M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $10M | — |
| Operating Income (EBIT) | ($77M) | ($71M) | ($48M) | ($55M) | ($37M) | — |
| Net Income | ($81M) | ($240M) | ($52M) | ($52M) | ($34M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $384M | $370M | $68M | $75M |
| Total Liabilities | $142M | $58M | $294M | $267M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZBIO viewer.
About TickerBase · Data methodology & sources